Lake Street Advisors Group LLC Increases Stock Position in Kenvue Inc. (NYSE:KVUE)

Lake Street Advisors Group LLC grew its stake in Kenvue Inc. (NYSE:KVUE) by 17.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,919 shares of the company’s stock after buying an additional 2,361 shares during the period. Lake Street Advisors Group LLC’s holdings in Kenvue were worth $340,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Longbow Finance SA grew its position in Kenvue by 5.0% in the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company’s stock worth $5,990,000 after acquiring an additional 13,287 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Kenvue by 1,415.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 139,684 shares of the company’s stock worth $2,982,000 after purchasing an additional 130,467 shares in the last quarter. Amalgamated Bank increased its position in shares of Kenvue by 0.5% during the 4th quarter. Amalgamated Bank now owns 378,249 shares of the company’s stock valued at $8,076,000 after purchasing an additional 1,932 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of Kenvue by 168.4% during the 4th quarter. IFP Advisors Inc now owns 12,197 shares of the company’s stock valued at $263,000 after buying an additional 7,652 shares in the last quarter. Finally, Howard Capital Management Inc. lifted its position in Kenvue by 5.5% in the 4th quarter. Howard Capital Management Inc. now owns 11,697 shares of the company’s stock worth $250,000 after buying an additional 607 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE opened at $23.15 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The stock has a market cap of $44.24 billion, a P/E ratio of 43.67, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45. The firm’s fifty day simple moving average is $21.42 and its 200 day simple moving average is $22.24.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.54%. The ex-dividend date was Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KVUE. UBS Group reduced their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Citigroup decreased their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. Barclays cut their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Canaccord Genuity Group decreased their price objective on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.